Codiak’s exoASO™-C/EBPβ Exosome-Based Treatment Demonstrates Significant Systemic Anti-Tumor Activity Via Targeting Immune-Suppressive Myeloid Cells in Preclinical Studies; Intravenous Exosome Candidate Engineered for Tropism Precisely Targets Transcription Factors in Myeloid Cell Subpopulations Using Luminal Anti-Sense Oligonucleotides (ASOs)

On April 8, 2022, Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced new preclinical data on the company’s engineered exosome precision medicine candidate, exoASO-C/EBPβ. The data, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate that exoASO-C/EBPβ induces potent single-agent anti-tumor activity by repolarizing myeloid cells in the tumor and blood to induce an immune response.